Rising old age population and higher incidences of neurodegenerative diseases are two significant factors that drive the growth of this market. Moreover, increasing R&D investment and number of drugs in the pipeline are further expected to fuel the market growth. However, high cost of treatment and lack of expertise for early diagnosis is likely to curtail the market growth.
The global Parkinson’s disease market is segmented on the basis of drug type and geography. According to drug type, the market is segmented into, marketed and pipeline drugs. The marketed drugs are further segmented into Levodopa, Dopamine agonists, Apomorphine, Glutamate antagonist, Anticholinergics, COMT inhibitors and MAO-B inhibitors. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.
Collaboration agreements and new product launches are few of the strategies adopted by the key industry players. For instance, in Jan 2015, Neuropore Therapies Inc. and UCB S.A, a Belgian drug maker entered into commercialization agreement for NPT200-11, a small molecule drug useful in debilitating the Parkinson’s disease. Recently, Impax Pharmaceuticals has announced the FDA approval for RYTARY, an extended release oral capsule for the treatment of Parkinson’s disease. Similarly AbbVie received a US FDA approval for DUOPA, used in the the treatment of motor symptoms associated with Parkinson’s disease.
The companies profiled in this report include, Pfizer, Inc., Medtronic plc, Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, C.H. Boehringer Sohn AG & Ko. KG, Impax Laboratories, Inc., Abbvie Inc., and F. Hoffmann-La Roche AG.
KEY MARKET BENEFITS:
Comprehensive analysis of factors that drive and restrict the growth of the global Parkinson’s disease market are provided
The report provides a comprehensive analysis of the current market and estimations through 2014-2020, which would enable the stakeholders to capitalize on prevailing market opportunities
Extensive analysis of the global Parkinson’s disease market by drug type helps in understanding the types of drugs that are currently used along with the variants that would gain prominence in future
SWOT analysis highlights the internal environment of the leading companies for strategy formulation
The Parkinson’s disease market scenario is comprehensively analysed in accordance to the key regions
Competitive intelligence highlights the business practises followed by leading market players across geographies
KEY MARKET SEGMENTS:
The global Parkinson’s disease market is segmented below:
Parkinson’s Disease Market - By Drug Type
Parkinson’s Disease Market - By Geography
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.